Milano | Division of Hematology & Oncology

Dr. Filippo Milano

Claim this profile

Fred Hutch/University of Washington Cancer Consortium

Studies Myelodysplastic Syndrome
Studies Acute Myeloid Leukemia
6 reported clinical trials
18 drugs studied

Area of expertise

1

Myelodysplastic Syndrome

Filippo Milano has run 4 trials for Myelodysplastic Syndrome. Some of their research focus areas include:

HLA-A positive
HLA-A negative
HLA negative
2

Acute Myeloid Leukemia

Filippo Milano has run 4 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

HLA-A positive
HLA-A negative
HLA negative

Affiliated Hospitals

Image of trial facility.

Fred Hutch/University Of Washington Cancer Consortium

Image of trial facility.

Fred Hutchinson / University Of Washington Cancer Consortium

Clinical Trials Filippo Milano is currently running

Image of trial facility.

Stem Cell Transplant

for Blood Cancers

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.

Recruiting

1 award

Phase 2

22 criteria

Image of trial facility.

Chemotherapy + Stem Cell Transplant

for Leukemia and Related Disorders

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy reduced-intensity conditioning regimen before stem cell transplant in treating patients with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Giving chemotherapy and total body irradiation before a donor peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells. Sometimes the transplanted cells from a donor can attack the body's normal cells called graft versus host disease. Giving cyclophosphamide, cyclosporine, and mycophenolate mofetil after the transplant may stop this from happening.

Recruiting

1 award

Phase 1

10 criteria

More about Filippo Milano

Clinical Trial Related

5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Filippo Milano has experience with

  • Total-Body Irradiation
  • Cyclophosphamide
  • Fludarabine
  • Cyclosporine
  • Mycophenolate Mofetil
  • Thiotepa

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Filippo Milano specialize in?

Is Filippo Milano currently recruiting for clinical trials?

Are there any treatments that Filippo Milano has studied deeply?

What is the best way to schedule an appointment with Filippo Milano?

What is the office address of Filippo Milano?

Is there any support for travel costs?